<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02872779</url>
  </required_header>
  <id_info>
    <org_study_id>2015/076/HP</org_study_id>
    <nct_id>NCT02872779</nct_id>
  </id_info>
  <brief_title>Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer</brief_title>
  <acronym>COCA-MACS</acronym>
  <official_title>Correlation Between Circulating Tumour Markers Early Variations and Clinical Response in First Line Treatment of Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The chemotherapy monitoring is currently based on radiological (RECIST 1.1 guideline) and&#xD;
      clinical evaluation every 3 months. Circulating markers as Carcino Embryonic Antigen (CEA),&#xD;
      circulating tumour DNA and total cell free DNA represent an alternative approach to evaluate&#xD;
      the response. In the field of metastatic colorectal cancer (mCRC) recent studies suggest that&#xD;
      early evaluation could be clinically relevant. Indeed, early tumoral response seems to be&#xD;
      correlated to overall survival. Moreover, post-operative morbidity increases with the number&#xD;
      of prior chemotherapy treatments. Early evaluation could allow to modify chemotherapy&#xD;
      regimens when response appears to be insufficient.&#xD;
&#xD;
      The aim of the present study is to evaluate, in a prospective cohort of patients treated with&#xD;
      systemic IV chemotherapy (5 Fluorouracil +/- oxaliplatin +/- irinotecan) +/- targeted therapy&#xD;
      as first line treatment for a mCRC, the correlation between early variations of circulating&#xD;
      tumour markers including CEA, circulating tumour DNA and total cell free DNA, and the 3&#xD;
      months objective response as defined in the RECIST 1.1 guideline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference from baseline in the number of free mutant DNA in blood</measure>
    <time_frame>5 weeks</time_frame>
    <description>Variation of free mutant DNA kinetic at week 5 to predict tumor progression at 3 months (Evaluation based on the RECIST 1.1 guideline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference from baseline in the number of free mutant DNA in blood</measure>
    <time_frame>3 weeks</time_frame>
    <description>Variation of free mutant DNA kinetic at week 3 to predict tumor progression at 3 months (Evaluation based on the RECIST 1.1 guideline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of response based on the RECIST 1.1 guideline</measure>
    <time_frame>3 Months</time_frame>
    <description>sensitivity and specificity of free mutant DNA kinetic at Week 5 (RECIST) to predict tumor progression at 3 months (RECIST)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Circulating Markers</condition>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Patients Treated for Metastatic Colorectal cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood sampling for free mutant DNA analysis for Patients Treated for Metastatic Colorectal cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling for free mutant DNA analysis</intervention_name>
    <description>Blood sampling for Patients Treated for Metastatic Colorectal cancer</description>
    <arm_group_label>Patients Treated for Metastatic Colorectal cancer</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, age superior to 18 years.&#xD;
&#xD;
          -  Histologically confirmed metastatic colorectal adenocarcinoma.&#xD;
&#xD;
          -  Measurable disease according to the RECIST 1.1 guideline&#xD;
&#xD;
          -  ECOG performance status &lt;3.&#xD;
&#xD;
          -  Disease requiring IV chemotherapy (5 Fluorouracil +/- oxaliplatin +/- irinotecan) +/-&#xD;
             targeted therapy (cetuximab or panitumumab or bevacizumab) every 14 days&#xD;
&#xD;
          -  No prior chemotherapy for this adenocarcinoma with the exception of adjuvant&#xD;
             chemotherapy&#xD;
&#xD;
          -  Signed and dated informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of cancer within 5 years&#xD;
&#xD;
          -  Medical contraindication for a treatment consisted of IV chemotherapy (5 Fluorouracil&#xD;
             +/- oxaliplatin +/- irinotecan) +/- targeted therapy (cetuximab or panitumumab or&#xD;
             bevacizumab)&#xD;
&#xD;
          -  Patient with known psychiatric or substance abuse disorders that could interfere with&#xD;
             cooperation with the requirements of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alice GANGLOFF, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alice GANGLOFF, MD</last_name>
    <email>alice.gangloff@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julien BLOT</last_name>
    <email>julien.blot@chu-rouen.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre MICHEL, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 16, 2016</study_first_submitted>
  <study_first_submitted_qc>August 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2016</study_first_posted>
  <last_update_submitted>August 21, 2017</last_update_submitted>
  <last_update_submitted_qc>August 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

